Combined Radiomodifying Effect of Fucoidan from the Brown Alga and Pacificusoside D from the Starfish in the Model of 3D Melanoma Cells
Overview
Molecular Biology
Authors
Affiliations
Cancer is one of the main causes of human mortality worldwide. Despite the advances in the diagnostics, surgery, radiotherapy, and chemotherapy, the search for more effective treatment regimens and drug combinations are relevant. This work aimed to assess the radiomodifying effect and molecular mechanism of action of fucoidan from the brown alga (ScF) and product of its autohydrolysis (ScF_AH) in combination with pacificusoside D from the starfish (SpD) on the model of viability and invasion of three-dimension (3D) human melanoma cells SK-MEL-2. The cytotoxicity of ScF (IC JB6 Cl41 > 800 µg/mL; IC SK-MEL-2 = 685.7 µg/mL), ScF_AH (IC JB6 Cl41/SK-MEL-2 > 800 µg/mL), SpD (IC JB6 Cl41 = 22 µM; IC SK-MEL-2 = 5.5 µM), and X-ray (ID JB6 Cl41 = 11.7 Gy; ID SK-MEL-2 = 6.7 Gy) was determined using MTS assay. The efficiency of two-component treatment of 3D SK-MEL-2 cells was revealed for ScF in combination with SpD or X-ray but not for the combination of fucoidan derivative ScF_AH with SpD or X-ray. The pre-treatment of spheroids with ScF, followed by cell irradiation with X-ray and treatment with SpD (three-component treatment) at low non-toxic concentrations, led to significant inhibition of the spheroids' viability and invasion and appeared to be the most effective therapeutic scheme for SK-MEL-2 cells. The molecular mechanism of radiomodifying effect of ScF with SpD was associated with the activation of the initiator and effector caspases, which in turn caused the DNA degradation in SK-MEL-2 cells as determined by the Western blotting and DNA comet assays. Thus, the combination of fucoidan from brown algae and triterpene glycoside from starfish with radiotherapy might contribute to the development of highly effective method for melanoma therapy.
Marine Natural Compounds with Biomedical Potential: 2nd Edition.
Leychenko E Biomolecules. 2024; 14(8).
PMID: 39199392 PMC: 11353120. DOI: 10.3390/biom14081005.
Ferreira R, Sousa Duarte S, Sousa V, de Souza R, Marques K, de Abrantes R Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004419 PMC: 10674350. DOI: 10.3390/ph16111553.
Ferreira R, do Nascimento Y, de Araujo Loureiro P, Martins R, de Souza Maia M, Farias D Biomolecules. 2023; 13(10).
PMID: 37892120 PMC: 10604947. DOI: 10.3390/biom13101439.
Usoltseva R, Zueva A, Malyarenko O, Anastyuk S, Moiseenko O, Isakov V Mar Drugs. 2023; 21(9).
PMID: 37755099 PMC: 10532595. DOI: 10.3390/md21090486.